Samy Suissa

3755 Côte Ste Catherine Road
Montreal, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 309 publications

Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial.

Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial.

Journal: BMJ (Clinical research ed.)

Published: August 05, 2026

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter].

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study [Response to Letter].

Journal: International journal of chronic obstructive pulmonary disease

Published: June 15, 2026

Transient Oral Corticosteroid Use and Acute Upper Gastrointestinal Bleeding in Mild-to-Moderate Asthma: A Case-Crossover Study.

Transient Oral Corticosteroid Use and Acute Upper Gastrointestinal Bleeding in Mild-to-Moderate Asthma: A Case-Crossover Study.

Journal: Drug safety

Published: April 07, 2026

Fluticasone- vs Budesonide-Based Dual Therapy for COPD.

Fluticasone- vs Budesonide-Based Dual Therapy for COPD.

Journal: JAMA network open

Published: March 09, 2026

Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease.

Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease.

Journal: JAMA internal medicine

Published: February 23, 2026

Initial Treatment of COPD with LABA-LAMA Versus LAMA: Real-World Comparative Effectiveness and Safety.

Initial Treatment of COPD with LABA-LAMA Versus LAMA: Real-World Comparative Effectiveness and Safety.

Journal: COPD

Published: February 19, 2026

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design.

Journal: Circulation

Published: February 12, 2026

Effectiveness of beta-blockers in COPD and CVD: Real-world effects on mortality.

Effectiveness of beta-blockers in COPD and CVD: Real-world effects on mortality.

Journal: Chest

Published: February 02, 2026

Antibiotics and Preterm Delivery: The Prevalent New-user Cohort Design to Resolve Immortal Time Bias.

Antibiotics and Preterm Delivery: The Prevalent New-user Cohort Design to Resolve Immortal Time Bias.

Journal: Epidemiology (Cambridge, Mass.)

Published: December 30, 2025

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study.

Comparative Effectiveness and Safety of Fluticasone-Umeclidinium-Vilanterol and Beclomethasone-Glycopyrronium-Formoterol Single-Inhaler Triple Therapies for COPD: Real-World Observational Study.

Journal: International journal of chronic obstructive pulmonary disease

Published: December 12, 2025

Influenza Immunization at Midlife and the Risk of Parkinson Disease.

Influenza Immunization at Midlife and the Risk of Parkinson Disease.

Journal: JAMA network open

Published: December 05, 2025

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.

Journal: Diabetes care

Published: October 21, 2025

Showing 1-12 of 309

Last Updated: 09/26/2026